This is a routine conference participation announcement with no new data. The next meaningful catalyst is the SAFEGUARD Phase 2b topline readout in 2H 2027. No trading action warranted based on this filing.
SABS drugs
SABS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 29 $3.60entry
- T+1 · 6mo ago −4.44%α −4.72% · $3.44
- T+5 · 6mo ago −6.67%α −6.37% · $3.36
- T+20 · 5mo ago +8.33%α +10.13% · $3.90
- T+60 · 3mo ago +0.56%α −0.63% · $3.62
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
SAB Biotherapeutics announced upcoming data presentations at the ADA and FOCIS conferences in June 2026, highlighting its lead program SAB-142 for type 1 diabetes. The press release contains no new clinical data, financial results, or regulatory milestones, it is a routine conference participation announcement with no material impact on the company's valuation.
Key Facts
- SAB BIO will present an oral presentation at ADA 2026 (June 5-8) and a poster at FOCIS 2026 (June 9-12).
- Presentations focus on SAB-142, a fully human anti-thymocyte immunoglobulin for Stage 3 type 1 diabetes.
- Topline data readout for the registrational Phase 2b SAFEGUARD study expected in 2H 2027.
- No new clinical data, financial figures, or regulatory decisions were disclosed in this press release.
Financial Impact
No financial impact, no new data, guidance, or material events disclosed.
Risk Factors
- SAB-142 is still in clinical development with no approved product; regulatory and clinical trial risks remain.
- Cash burn and financing risk for a clinical-stage biotech with no revenue.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303527 |
Track record
15 reports on SABS
3 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +15.67% at T+20 after the Oct 13, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $3.00 Now $3.00 0.00% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $2.96 Now $3.00 +1.35% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.00 Now $3.00 0.00% settles Dec 15
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $2.94 Now $3.00 +2.04% settles Dec 4
- Oct 22, 202625d ago 25-NSE Neutral 2/10 Entry $2.84 Now $3.00 +5.63% settles Nov 20
- Oct 13, 20264w ago 8-K Bullish 6/10 Entry $2.68 to $3.07 Now $3.00 +11.94% ▲ +14.55% +18.16% vs SPY
- Oct 13, 20264w ago Press Release Bullish 5/10 Entry $2.68 to $3.10 Now $3.00 +11.94% ▲ +15.67% +19.34% vs SPY
- Jul 7, 202618w ago 8-K Bullish 4/10 Entry $3.90 to $3.79 Now $3.00 −23.08% ▼ −2.82% −4.15% vs SPY
- May 29, 202624w ago Press Release Neutral 3/10 Viewing Entry $3.60 to $3.90 Now $3.00 −16.67% ▲ +8.33% +10.13% vs SPY
- May 12, 202626w ago Press Release Bearish 7/10 Entry $3.62 to $3.31 Now $3.00 +17.13% ▲ +8.56% +6.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers